CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Shares withheld for taxes Chief Legal Officer gave up 7,893 shares (to pay taxes)
- 4 Planned sale President and CEO sold 45,000 shares at $19.69 ($885,825)
- 4 Grant or award Director acquired 3,486 shares (grant or award)
- 4 Grant or award Director acquired 3,486 shares (grant or award)
- 4 Grant or award Director acquired 3,486 shares (grant or award)
- 4 Grant or award Director acquired 3,486 shares (grant or award)
- 4 Grant or award Director acquired 3,486 shares (grant or award)
- 4 Grant or award Director acquired 3,486 shares (grant or award)
- 4 Grant or award Director acquired 3,486 shares (grant or award)
- 4 Grant or award Director acquired 3,486 shares (grant or award)
- 4 Exercise or conversion Chief Financial Officer acquired 35,000 shares (option exercise)
- 4 Shares withheld for taxes Chief Financial Officer gave up 1,333 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Oper. & Tech. Officer gave up 2,076 shares (to pay taxes)
- 4 Open-market sale Chief Medical Officer sold 3,138 shares at $22.17 ($69,559)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 2,058 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 9,308 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Legal Officer gave up 1,843 shares (to pay taxes)
- 4 Open-market sale Chief Financial Officer sold 2,400 shares at $30.24 ($72,573)
- 4 Open-market sale Chief Financial Officer sold 17,680 shares at an average $35.18 ($622,035)
- 4 Open-market sale Chief Financial Officer sold 2,400 shares at $31.26 ($75,012)
Page 6 of 22 · 435 filings